CD19 and precursor B-cell acute lymphoblastic leukemia: The Food Drug Administration (FDA) subsequently approved the anti-CD3 × anti-CD19 bispecific T-cell engager blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia (ALL).7 FDA approval of this drug was based on the results of the multicentre, open-label, single-arm Phase 2 BLAST clinical trial (NCT01207388), in which 78% of patients with B-cell ALL achieved a complete minimal residual disease (MRD) response after just one cycle of treatment.